Abstract
BackgroundBispecific antibodies (BsAbs) are gaining momentum in several immunotherapeutic1 2 3 and immuno-oncology settings.4 Certain designs of BsAbs enable tumor-specific targeting when two targets are concurrently expressed on tumor but...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have